Changes in Vascularization of Human Breast Cancer Xenografts Responding to Antiestrogen Therapy

Neoplasia

Volumn 1, Issue 6, 1999, Pages 518-525

  Kristensen, Claus A ^a,b   Hamberg, Leena M ^a   Hunter, George J ^a   Roberge, Sylvie ^a   Kierstead, Diane ^a   Wolf, Gerald L ^a   Jain, Rakesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Breast cancer; Estrogen withdrawal; Functional CT scanning; Tamoxifen; Vascular resistance

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; LYMPHOKINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; INFANT; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; VASCULARIZATION; XENOGRAFT;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; ESTROGEN RECEPTOR MODULATORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFANT; LYMPHOKINES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033287181     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900063     Document Type: Article

References (49)

1. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31.
2. Shweiki D, Neeman M, Itin A, and Keshet E (1995). Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Pros Natl Acad Sci U S A 92, 768-772.
3. Skobe M, Rockwell P, Goldstein N, Vosseler S, and Fusenig NE 1997). Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3, 1222-1227.
4. Rak J, and Kerbel RS (1997). bFGF and tumor angiogenesis - back in the limelight? Nat Med 3, 1083-1084.
5. Yoshiji H, Harris SR, and Thorgeirsson UP (1997). Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57, 3924-3928.
6. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, and Folkman J (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
7. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
8. Gradishar WJ (1997). An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Invest New Drugs 15, 49-59.
9. Early Breast Cancer Trialists' Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: Part 1. Lancet 339, 1-15.
10. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, and Dickson RB (1987). Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48, 417-428.
11. Faye J-C, Jozan S, Redeuilh G, Baulieu E-E, and Bayard F (1983). Physicochemical and genetic evidence for specific antiestrogen binding sites. Proc Natl Acad Sci U S A 80, 3158-3162.
12. Murphy LC, and Sutherland RL (1981). A high-affinity binding site for the antioestrogens, tamoxifen and Cl 628, in immature rat uterine cytosol which is distinct from the oestrogen receptor. J Endocrinol 91, 155-161.
13. 31P MRS, creatine kinase activity, and apoptotic index. Cancer Res 55, 4146-4150.
14. Furman-Haran E, Maretzek AF, Goldberg I, Horowitz A, and Degani H (1994). Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 54, 5511-5514.
15. Nakamura J, Savinov A, Lu Q, and Brodie A (1996). Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology 137, 5589-5596.
16. Johns A, Freay AD, Fraser W, Korach KS, and Rubanyi GM (1996). Disruption of estrogen receptor gene prevents 17β estradiol-induced angiogenesis in transgenic mice. Endocrinology 137, 4511-4513.
17. Gagliardi A, and Collins DC (1993). Inhibition of angiogenesis by antiestrogens. Cancer Res 53, 533-535.
18. Gagliardi AR, Hennig B, and Collins DC (1996). Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 16, 1101-1106.
19. McLeskey SW, Zhang L, El-Ashry D, Trock BJ, Lopez CA, Kharbanda S, Tobias CA, Lorant LA, Hannum RS, Dickson RB, and Kern, FG (1998). Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. Clin Cancer Res 4, 697-711.
20. Fagrell B, and Intaglietta M (1997). Microcirculation: its significance in clinical and molecular medicine. J Int Med 241, 349-362.
21. Hamberg LM, Kristjansen PEG, Hunter GJ, Wolf GL, and Jain RK (1994). Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 μl resolution. Cancer Res 54, 6032-6036.
22. Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, and Harris AL (1992). Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340, 1120-1124.
23. Sevick EM, and Jain RK (1989). Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 49, 3506-3512.
24. 1H magnetic resonance spectroscopic studies. Br J Cancer 79, 278-285.
25. Kristensen CA, Roberge S, and Jain RK (1997). Effect of tumor necrosis factor α on vascular resistance, nitric oxide production, and glucose and oxygen consumption in perfused tissue-isolated human melanoma xenografts. Clin Cancer Res 3, 319-324.
26. Kristjansen PEG, Brown TJ, Shipley LA, and Jain RK (1996). Intratumor pharmacokinetics, flow resistance, and metabolism during gemcitabine infusion in ex vivo perfused human small cell lung cancer. Clin Cancer Res 2, 359-367.
27. Kristjansen PEG, Roberge S, Lee I, and Jain RK (1994). Tissue-isolated human tumor xenografts in athymic nude mice. Microvasc Res 48, 389-402.
28. Groothuis DR, Lapin GD, Vriesendorp FJ, Mikhael MA, and Patlak CS (1991). A method to quantitatively measure transcapillary transport of iodinated compounds in canine brain tumors with computed tomography. J Cereb Blood Flow Metab 11, 939-948.
29. Weidner N (1995). Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36, 169-180.
30. el Ashry D, and Lippman ME (1994). Molecular biology of breast carcinoma. World J Surg 18, 12-20.
31. Kyprianou N, English HF, Davidson NE, and Isaacs JT (1991). Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51, 162-166.
32. Wärri AM, Huovinen RL, Laine AM, Martikainen PM, and Härkönen PL (1993). Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85, 1412-1418.
33. Cameron DA, Ritchie AA, Langdon S, Anderson TJ, and Miller WR (1997). Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res Treat 45, 99-107.
34. Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE, and Dowsett M (1997). Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 72, 608-613.
35. Otto AM, Paddenberg R, Schubert S, and Mannherz HG (1996). Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 122, 603-612.
36. Colecchia M, Frigo B, Del Boca C, Guardamagna A, Zucchi A, Colloi D, and Leopardi O (1997). Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. J Clin Pathol 50, 384-388.
37. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, and Harkonen PL (1999). Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 149, 29-40.
38. Fuqua S.A.W. (1994). Estrogen receptor mutagenesis and hormone resistance. Cancer 74, 1026-1029.
39. Pavlik EJ, Nelson K, Srinivasan S, Powell DE, Kenady DE, DePriest PD, Gallion HH, and van Nagell JR, Jr (1992). Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res 52, 4106-4112.
40. Sensky PL, Prise VE, Tozer GM, Shaffi KM, and Hirst DG. Resistance to flow through tissue-isolated transplanted rat tumours located in two different sites. Br J Cancer 67, 1337-1341.
41. Less JR, Skalak TC, Sevick EM, and Jain RK (1991). Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51, 265-273.
42. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, and Keshet E (1998). Endothelial cell death, angiogenesis and microvascular function following castration in an androgen dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95, 10820-10825.
43. Gazit Y, Baish JW, Safabakhsh N, Leunig M, Baxter LT, and Jain RK (1997). Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation 4, 395-402.
44. Pemberton KD, Melissari E, and Kakkar VV (1993). The influence of tamoxifen on the main natural anticoagulants and fibrinolysis. Blood Coagulation, Fibrinolysis 4, 935-942.
45. Evans SM, Koch CJ, Laughlin KM, Jenkins WT, Van Winkle T, and Wilson DF (1997). Tamoxifen induces hypoxia in MCF-7 xenografts. Cancer Res 57, 5155-5161.
46. Tannock IF (1996). Treatment of cancer with radiation and drugs. J Clin Oncol 14, 3156-3174.
47. Kantorowitz DA, Thompson HJ, and Furmanski P (1993). Effect of conjoint administration of tamoxifen and high-dose radiation on the development of mammary carcinoma. Int J Radiat Oncol Biol Phys 26, 89-94.
48. Cooke AL, Perera F, Fisher B, Opeitum A, and Yu N (1995). Tamoxifen with and without radiation after partial mastectomy in patients with involved nodes. Int J Radiat Oncol Biol Phys 31, 777-781.
49. Zietman AL, Nakfoor BM, Prince EA, and Gerweck LE (1997). The effect of androgen deprivation and radiation therapy on an androgen sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 3, 31-36.